Effects of anti-osteoporosis medications on total hip arthroplasty risks in osteoporotic patients with hip osteoarthritis in Taiwan: a nationwide cohort study
- 77 Downloads
This nationwide cohort study examined the potential disease-modifying effect of anti-osteoporosis medication on hip osteoarthritis. The results revealed that the usage of anti-osteoporosis medication is not associated with decreased risk in undergoing total hip arthroplasty in patient with hip osteoarthritis.
This study aimed to assess the association between use of anti-osteoporosis medications (AOMs) and the risk of undergoing total hip arthroplasty (THA) in patients with hip osteoarthritis (OA).
Using the 2008–2013 National Health Insurance Research Database, we identified patients who were first diagnosed as having hip OA. All identified patients were followed until THA, death of any cause, or December 31, 2013, whichever occurred first. All AOM exposures were divided into three categories: bisphosphonates use, non-bisphosphonates use, and no use of AOMs and assessed in a time-varying manners. The primary outcome was THA. The secondary outcome was the differences in the longitudinal utilization of NSAIDs between AOM users and non-users. Time-dependent Cox proportional hazards models were used to investigate the effect of AOM use on the risk of THA.
We identified 35,870 patients who were first diagnosed as having hip OA and had no history of AOM use between 2009 and 2012. Among them, 3162 and 1667 patients had their first prescription of bisphosphonates and other non-bisphosphonates AOMs during the follow-up period. Mean age of bisphosphonates users, non-bisphosphonates users, and non-users was 75.62, 76.84, and 67.39 years, respectively. Bisphosphonates or non-bisphosphonates users did not show significant change when compared to non-users in terms of risk of undergoing THA [adjusted hazard ratio (aHR) 0.972, 95% confidence interval (CI) 0.743–1.273; aHR 0.926, 95% CI 0.672–1.277].
Our results showed that the use of AOMs is not associated with decreased risk of THA in patients with hip OA.
KeywordsOsteoporosis Hip osteoarthritis Total hip arthroplasty Anti-osteoporosis medications
The study was funded by the National Taiwan University Hospital, Yun-Lin branch (grant number NTUHYL105.N002).
Compliance with ethical standards
Conflicts of interest
All procedures performed in studies involving human participants were in accordance with the ethical standards of the Research Ethics Committee of National Taiwan University Hospital (NTUH-REC-201510092W) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
For this retrospective type of study, formal consent is not required.
- 1.Hiligsmann M, Cooper C, Arden N, Boers M, Branco JC, Brandi ML et al (2013) Health economics in the field of osteoarthritis: an expert's consensus paper from the European Society for Clinical and Economic Aspects of osteoporosis and osteoarthritis (ESCEO). Semin Arthritis Rheum 43(3):303–313. https://doi.org/10.1016/j.semarthrit.2013.07.003 CrossRefPubMedPubMedCentralGoogle Scholar
- 3.Salmon JH, Rat AC, Sellam J, Michel M, Eschard JP, Guillemin F, Jolly D, Fautrel B (2016) Economic impact of lower-limb osteoarthritis worldwide: a systematic review of cost-of-illness studies. Osteoarthr Cartil 24(29):1500–1508. https://doi.org/10.1016/j.joca.2016.03.012 CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Ahlbäck S (1968) Osteoarthrosis of the knee. A radiographic investigation. Acta Radiol Diagn (Stockh) Suppl 277:7–72Google Scholar
- 9.Neuprez A, Neuprez AH, Kurth W, Gillet P, Bruyère O, Reginster JY (2018) Profile of osteoarthritic patients undergoing hip or knee arthroplasty, a step toward a definition of the "need for surgery". Aging Clin Exp Res 30:315–321. https://doi.org/10.1007/s40520-017-0780-1 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Bruyère O, Cooper C, Arden N, Branco J, Brandi ML, Herrero-Beaumont G, Berenbaum F, Dennison E, Devogelaer JP, Hochberg M, Kanis J, Laslop A, McAlindon T, Reiter S, Richette P, Rizzoli R, Reginster JY (2015) Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis. Drugs Aging 32:179–187. https://doi.org/10.1007/s40266-015-0243-3 CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden NK, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P (2008) OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil 16(2):137–162. https://doi.org/10.1016/j.joca.2007.12.013 CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P (2010) OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil 18(4):476–499. https://doi.org/10.1016/j.joca.2010.01.013 CrossRefGoogle Scholar
- 16.Carbone LD, Nevitt MC, Wildy K, Barrow KD, Harris F, Felson D, Peterfy C, Visser M, Harris TB, Wang BW, Kritchevsky SB (2004) Health, aging and body composition study. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis Arthritis Rheum 50(11):3516–3525. https://doi.org/10.1002/art.20627 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Bingham CO 3rd, Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S, Clauw DJ, Spector TD, Pelletier JP, Raynauld JP, Strand V, Simon LS, Meyer JM, Cline GA, Beary JF (2006) Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 54(11):3494–3507. https://doi.org/10.1002/art.22160 CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Garnero P, Aronstein WS, Cohen SB, Conaghan PG, Cline GA, Christiansen C, Beary JF, Meyer JM, Bingham CO 3rd (2008) Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the knee osteoarthritis structural arthritis randomized clinical trial. Osteoarthr Cartil 16(6):660–666. https://doi.org/10.1016/j.joca.2007.10.002 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Fu SH, Wang CY, Yang RS, Wu FL, Hsiao FY (2017) Bisphosphonate use and the risk of undergoing total knee arthroplasty in osteoporotic patients with osteoarthritis: a nationwide cohort study in Taiwan. J Bone Joint Surg Am 99(11):938–946. https://doi.org/10.2106/JBJS.16.00385 CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Olivier E, Bruyère O, Richy F, Dardennes C, Reginster JY (2004) Health-related quality of life in total hip and total knee arthroplasty: a qualitative and systematic review of the literature. J Bone Joint Surg Am 86-A(5):963–974Google Scholar
- 26.Hsiao FY, Yang YC, Huang YT, Huang WF (2007) Using Taiwan’s National Health Insurance Research Databases for pharmacoepidemiology research. J Food Drug Anal 15:99–108Google Scholar
- 34.Karlsson L, Lundkvist J, Psachoulia E, Intorcia M, Ström O (2015) Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int 26(10):2401–2411. https://doi.org/10.1007/s00198-015-3253-4 CrossRefPubMedPubMedCentralGoogle Scholar
- 43.Taljanovic MS, Graham AR, Benjamin JB, Gmitro AF, Krupinski EA, Schwartz SA, Hunter TB, Resnick DL (2008) Bone marrow edema pattern in advanced hip osteoarthritis: quantitative assessment with magnetic resonance imaging and correlation with clinical examination, radiographic findings and histopathology. Skelet Radiol 37(5):423–431. https://doi.org/10.1007/s00256-008-0446-3 CrossRefGoogle Scholar
- 45.Reginster JY, Reiter-Niesert S, Bruyère O, Berenbaum F, Brandi ML, Branco J, Devogelaer JP, Herrero-Beaumont G, Kanis J, Maggi S, Maheu E, Richette P, Rizzoli R, Cooper C (2015) Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement. Osteoarthr Cartil 23(12):2086–2093. https://doi.org/10.1016/j.joca.2015.07.001 CrossRefPubMedPubMedCentralGoogle Scholar